Tracers / [89Zr]Zr-DFO-girentuximab
[89Zr]Zr-DFO-girentuximab
Also written as [89Zr]Zr-DFO-girentuximab
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- PET
- Production route
- —
- Stage
- clinical proof-of-concept / prospective pilot study
- Syntheses indexed
- 4
What it is
- Compound class
- Radiolabeled monoclonal antibody (anti-CA-IX chimeric antibody, DFO-conjugated)
- Target / mechanism
- Targets Carbonic Anhydrase IX (CA-IX) antigen PMID 41174094
- Clinical application
- PET/CT imaging of CA-IX-expressing tumors PMID 41174094
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — Telix International | — | — | — | — | girentuximab Telix International Pty Ltd | 41174094 2026 Eur J Nucl Med Mol Imaging |
| Manual synthesis | — | SPE | 87 | >95% | H3DFOSq-girentuximab | 41631002 2026 Gastro Hep Adv [89Zr]ZrIV in 0.05 M oxalic acid (250 μL, 165 MBq, Austin Health) was neutralized with sodium acetate buffer — combined to a given 143 MBq (87% isolated radiochemical yeild) in 3 mL with >95% radiochemical purity |
| — Telix International | — | — | — | — | girentuximab (DFO-girentuximab) Telix International Pty Ltd | 41174094 2026 Eur J Nucl Med Mol Imaging |
| Manual synthesis | — | — | — | — | — | 40227816 2025 Cancers (Basel) Patients had one intravesical instillation of 37 ± 10% MBq of [89Zr]Zr-girentuximab (10 mg antibody mass dose) |
Need this precursor?We can point you to suppliers for [89Zr]Zr-DFO-girentuximab, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [89Zr]Zr-DFO-girentuximab.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with Zr-89. Stage set/updated at stage 23 from PMID 40227816: 'Additionally, a clinical proof-of-concept study, PERTINENCE, that used [89Zr]Zr-girentuximab for PET/CT imaging in bladder cancer patients was conducted.'. | Stage 28: added indication(s) onc-bladder from consolidated missing-rubric review.